Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

dures, and there is currently not a good solution for this challenging lesion subset."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit http://www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, unexpected delays or costs associated with the Company's relocation and consolidation of its headquarters and manufacturing operations, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. Fo
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... the issuance of an aggregate of 30,000 stock options ... aggregate of 120,500 stock options to employees and consultants ... three years and will be exercisable for a period ... per stock option. About Covalon Covalon ...
(Date:3/27/2015)... LAKE CITY , March 27, 2015 Dynatronics ... J. Linder has been appointed to the Company,s Board ... created by the death in November 2014 of board member ... Rich Linder to our Board of Directors represents ... Cullimore, Jr. , chairman and president of Dynatronics.  "Rich is ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2
... , , NASHVILLE, Tenn. ... leading provider of medical cost management services, today commended two ... CT scans and other diagnostic imaging tests. , "When ... treatment," said Gregg Allen, M.D., chief medical officer of MedSolutions. ...
... , ATLANTA, Dec. 16 Medlytix, a ... a key half-billion dollar milestone - the total amount of ... to more than a half-million patients nationwide by doing a ... than two years. , "We,re proud that each of these ...
Cached Medicine Technology:MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3Healthcare Scoring System Allows Hospitals To Increase Charity Care 2Healthcare Scoring System Allows Hospitals To Increase Charity Care 3Healthcare Scoring System Allows Hospitals To Increase Charity Care 4
(Date:3/28/2015)... 28, 2015 Andrew Hawley of Vintage Rock ... psychedelic concert posters. The Who and the Doors played together ... 2, 1968. According to Hawley, “The Who toured the United ... and college campuses. Perhaps the most famous Who poster was ... and the Doors on August 2, 1968 at the Singer ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... 28, 2015 Servpro of Paso ... week released a report about the link between mold ... sufferers, and according to recent medical research, may even ... to the Environmental Protection Agency, people with sensitivity to ... in mold may trigger asthma attacks for asthma sufferers. ...
Breaking Medicine News(10 mins):Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... peers are doing seems to matter, expert surmise, , MONDAY, ... friends really weren,t drinking as much as it might seem, ... , Researchers from Oxford Brookes University in England reviewed 22 ... States. The researchers divided the students into two groups: those ...
... NASHVILLE, Tenn., July 20 HealthLeaders-InterStudy, a leading ... the Los Angeles market are struggling to recruit physicians, particularly ... the recent Los Angeles Market Overview , ... to physicians, ranging from $250 to $4,000 a day, to ...
... , PITTSBURGH, July 20 Mylan Inc. (Nasdaq: ... million preferred stock issuance, the company has declared its quarterly dividend of ... a liquidation preference of $1,000.00 per share) payable on August 17, 2009, ... , , Mylan Inc., which provides products ...
... , SEATTLE, July 20 Group Health ... 15 quality measures in the Puget Sound Health Alliance Community ... any of the other nine medical groups in the Puget Sound region ... Health received no "below regional average" scores. , , ...
... , , CLEVELAND, July 20 ... global eClinical solutions for the clinical trials industry, announced today that ... DATATRAK CRO Connect Program(TM). ARA will utilize DATATRAK eClinical(TM) to ... paper and EDC clients. , , ...
... , , ... 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced that ... drug for the treatment of obesity, met their co-primary endpoints. The results ... besity R esearch, or COR, program of more than 4,500 ...
Cached Medicine News:Health News:Perception May Affect Drinking by College Students 2Health News:l.a. Hospitals Struggle for Emergency Room Care, Pay Physicians High Fees for On-Call Coverage 2Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 3Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9
... Endo-Surgery provides clip appliers in 10mm and ... appliers provide precise clip placement., ,The ... These preloaded, single-trigger instruments are designed to ... a 5mm trocar, through a 5mm reducer ...
... and IMMULITE 1000 assays are ... IMMULITE and IMMULITE 1000, continuous ... offer simplicity in both design ... be found in a wide ...
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... new windows for the laboratory in flexibility, ... move from one function to another. You ... and add a new patient record simultaneously. ... track of all the open functions and ...
Medicine Products: